Having apparently given up on first line intra-tumoral treatment they now hope to salvage the pipeline as a combination therapy.
This company had in the past been relying on their electroporation delivery as the primary investment thesis. There been little interest in intratumoral treatment irrespective of the delivery method.
Used to see this company as quasi-legitimate about five years ago.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.